Published in Breast Cancer Res Treat on March 15, 2012
Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. Clin Cancer Res (2015) 2.01
Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res (2014) 1.43
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int (2014) 1.21
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer (2014) 1.14
Treatment of HER2-positive breast cancer. Breast (2013) 1.09
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer (2014) 1.03
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther (2013) 0.99
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget (2013) 0.97
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs (2012) 0.96
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. J Hematol Oncol (2014) 0.94
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget (2014) 0.93
Targeted therapy in HER2-positive breast cancer. Biomed Rep (2013) 0.91
Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience (2013) 0.89
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. J Adv Pract Oncol (2015) 0.89
Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist (2014) 0.89
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs (2012) 0.89
Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. Oncotarget (2014) 0.88
Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. Breast Cancer (Auckl) (2014) 0.87
Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) (2015) 0.85
Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2012) 0.84
Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J Gastroenterol (2013) 0.82
Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. World J Clin Oncol (2014) 0.82
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clin Pharmacokinet (2017) 0.80
Targeting HER2 Positive Breast Cancer with Chemopreventive Agents. Curr Pharmacol Rep (2015) 0.80
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol (2015) 0.79
Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer. Curr Breast Cancer Rep (2014) 0.79
ErbB2 signaling at the crossing between heart failure and cancer. Basic Res Cardiol (2016) 0.79
Network understanding of herb medicine via rapid identification of ingredient-target interactions. Sci Rep (2014) 0.78
A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. Springerplus (2016) 0.78
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer (2014) 0.78
HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK. PLoS One (2016) 0.78
Recent developments and translational aspects in targeted therapy for metastatic breast cancer. ESMO Open (2016) 0.76
Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma. Am J Cancer Res (2017) 0.75
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. Cancer Biol Ther (2014) 0.75
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Med (2016) 0.75
Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer. Breast Care (Basel) (2016) 0.75
Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Curr Pharm Des (2016) 0.75
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer. Int J Mol Sci (2016) 0.75
Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. Drug Des Devel Ther (2015) 0.75
Cancer and the metastatic substrate. Ecancermedicalscience (2016) 0.75
Identification of driver copy number alterations in diverse cancer types and application in drug repositioning. Mol Oncol (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res (2007) 5.01
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol (2010) 4.94
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst (2007) 4.03
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 3.62
Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist (2002) 2.62
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2010) 2.34
Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res (2009) 1.98
Trastuzumab: triumphs and tribulations. Oncogene (2007) 1.94
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist (2007) 1.78
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol (2008) 1.66
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J (2006) 1.65
Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci (2010) 1.27
HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets (2009) 1.25
Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia (2009) 1.14
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension (2007) 5.80
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med (2013) 4.23
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol (2004) 4.03
Informing clinical trial participants about study results. JAMA (2002) 3.76
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol (2008) 3.04
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90
Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion (2008) 2.87
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer (2008) 2.82
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med (2013) 2.76
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol (2011) 2.71
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer (2010) 2.63
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) (2012) 2.50
Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev (2006) 2.48
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol (2010) 2.47
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol (2013) 2.35
Do patients participating in clinical trials want to know study results? J Natl Cancer Inst (2003) 2.33
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol (2011) 2.30
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst (2010) 2.28
Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol (2006) 2.24
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res (2013) 2.09
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol (2005) 2.09
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol (2012) 2.07
Obesity and recurrent vascular risk after a recent ischemic stroke. Stroke (2011) 2.04
What is triple-negative breast cancer? Eur J Cancer (2008) 2.01
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst (2014) 1.96
Offering participants results of a clinical trial: sharing results of a negative study. Lancet (2005) 1.90
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw (2006) 1.88
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol (2007) 1.85
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest (2008) 1.80
Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol (2007) 1.77
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol (2011) 1.72
The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion (2007) 1.70
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol (2008) 1.69
Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg (2006) 1.69
Discussion of fertility preservation with newly diagnosed patients: oncologists' views. J Cancer Surviv (2007) 1.68
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics (2011) 1.67
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65